MLV & Co Upgrades Acura Pharmaceuticals To Buy

Analysts MLV & Co upgraded Acura Pharmaceuticals, Inc. ACUR from Hold to Buy. The price target for Acura Pharmaceuticals is set to $1. Acura Pharmaceuticals shares have dropped 61.62% over the past 52 weeks, while the S&P 500 index has surged 13.51% in the same period. Acura Pharmaceuticals' shares rose 6.76% to $0.79 in after-hours trading.